The Clonal Evolution and Therapeutic Approaches of Lung Cancer

Cell Biochemistry and Biophysics

Volumn 70, Issue 1, 2014, Pages 63-71

  Yu, Haixiang ^a   Han, Zhenguo ^a   Wang, Yue ^a   Xin, Hua ^a  

^a CHINA JAPAN UNION HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

Clonal origin of evolution; Immunohistological classification; Lung cancer; Molecular profiling; Therapeutic approaches of lung cancer

Indexed keywords

ANIMAL; CLONAL EVOLUTION; GENETICS; HUMAN; LUNG NEOPLASMS; PATHOLOGY;

ANIMALS; CLONAL EVOLUTION; HUMANS; LUNG NEOPLASMS;

EID: 84906236344     PISSN: 10859195     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12013-014-9910-y     Document Type: Review

References (68)

1. Travis, W. D., Brambilla, E., Muller-Hermelink, H. K., & Harris, C. C. (2004). Pathology and Genetics of Tumours of the Lung, Pleura, Thymus, and Heart, World Health Organization Classification of Tumours. Lyon: IARC.
2. Nicholson, A. G., Gonzalez, D., Shah, P., Pynegar, M. J., Deshmukh, M., Rice, A., et al. (2010). Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of Mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis. Journal of Thoracic Oncology, 5, 436-441.
3. Peto, R., Lopez, A. D., Boreham, J., Thun, M., & Heath, C, Jr. (1994). Mortality from smoking in developed countries 1950-2000 (Vol. 143, p. 658). Indirect Estimates from National Vital Statistics: Oxford University Press, New York.
4. Sridhar, S. S., Seymour, L., & Shepherd, F. A. (2003). Inhibitors of epidermal-growth-factor receptors: A review of clinical research with a focus on non-small-cell lung cancer. Lancet Oncology, 4, 397-406.
5. Sawyers, C. L. (2002). Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia. Cancer Cell, 1, 413-415.
6. Hollinshead, A., Stewart, T. H. M., Takita, H., Dalbow, M., & Concannon, J. (1987). Adjuvant specific active lung cancer immunotherapy trials. Tumor-associated antigens. Cancer, 60, 1249-1262.
7. Mazzone, P. (2012). Preoperative evaluation of the lung resection candidate. Cleveland Clinic Journal of Medicine, 79, eS17-eS22.
8. Beane, J., Sebastiani, P., Whitfield, T. H., Steiling, K., Dumas, Y. M., Lenburg, M. E., et al. (2008). A prediction model for lung cancer diagnosis that integrates genomic and clinical features. Cancer Prevention Research, 1, 56-64.
9. Yildiz, P. B., Shyr, Y., Rahman, J. S., Wardwell, N. R., Zimmerman, L. J., Shakhtour, B., et al. (2007). Diagnostic accuracy of MALDI mass spectrometric analysis of unfractionated serum in lung cancer. Journal of Thoracic Oncology, 2, 893-901.
10. Saracci, R., & Boffetta, P. (1994). Interactions of tobacco smoking and other causes of lung cancer. In J. M. Samet (Ed.), Epidemiology of lung cancer (pp. 465-493). New York, NY: Marcel Dekker.
11. Samet, J. M., & Cohen, A. J. (1999). Air pollution and lung cancer. In S. Holgate, J. M. Samet, H. S. Koren, et al. (Eds.), Air pollution and health (pp. 841-864). San Diego, CA: Academic Press.
12. Willett, W. C. (1995). Diet, nutrition, and avoidable cancer. Environmental Health Perspectives, 103(suppl 8), 165-170.
13. Samet, J. M. (1995). Lung cancer. In P. Greenwald, B. S. Kramer, & D. L. Weed (Eds.), Cancer prevention and control (pp. 561-584). New York, NY: Marcel Dekker.
14. Health effects of exposure to radon (BEIR VI) (1999). Washington, DC: National Academy Press, National Research Council, Committee on Health Risks of Exposure to Radon, Board on Radiation Effects Research, Commission on Life Sciences.
15. Spira, A., Beane, J., Shah, V., Liu, G., Schembri, F., Yang, X., et al. (2004). Effects of cigarette smoke on the human airway epithelial cell transcriptome. Proceedings of the National Academy of Sciences United States of America, 101, 10143-10148.
16. Park, I. W., Wistuba, I. I., Maitra, A., Milchgrub, S., Virmani, A. K., Minna, J. D., et al. (1999). Multiple clonal abnormalities in the bronchial epithelium of patients with lung cancer. Journal of the National Cancer Institute, 91, 1863-1868.
17. Maley, C. C., Galipeau, P. C., Finley, J. C., Wongsurawat, V. J., Li, X., Sanchez, C. A., et al. (2006). Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nature Genetics, 38, 468-473.
18. Wistuba, I. I., Mao, L., & Gazdar, A. F. (2002). Smoking molecular damage in bronchial epithelium. Oncogene, 21, 7298-7306.
19. Westra, W. H. (2000). Early glandular neoplasia of the lung. Respiratory Research, 1, 163-169.
20. Sato, M., Shames, D. S., Gazdar, A. F., & Minna, J. D. (2007). A translational view of the molecular pathogenesis of lung cancer. Journal of Thoracic Oncology, 2, 327-343.
21. Tang, X., Shigematsu, H., Bekele, B. N., Roth, J. A., Minna, J. D., Hong, W. K., et al. (2005). EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients. Cancer Research, 65, 7568-7572.
22. Guo, M., House, M. G., Hooker, C., Han, Y., Heath, E., Gabrielson, E., et al. (2004). Promoter hypermethylation of resected bronchial margins: A field defect of changes? Clinical Cancer Research, 10, 5131-5136.
23. Brock, M. V., Hooker, C. M., Ota-Machida, E., Han, Y., Guo, M., Ames, S., et al. (2008). DNA methylation markers and early recurrence in stage I lung cancer. New England Journal of Medicine, 358, 1118-1128.
24. Kim, J. S., Kim, J. W., Han, J., Shim, Y. M., Park, J., & Kim, D. H. (2006). Cohypermethylation of p16 and FHIT promoters as a prognostic factor of recurrence in surgically resected stage I non-small cell lung cancer. Cancer Research, 66, 4049-4054.
25. Belinsky, S. A., Klinge, D. M., Stidley, C. A., Issa, J. P., Herman, J. G., March, T. H., et al. (2003). Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer. Cancer Research, 63, 7089-7093.
26. Xu, B., Thong, N., Tan, D., & Khoury, T. (2010). Expression of thyroid transcription factor-1 in colorectal carcinoma. Applied Immunohistochemistry and Molecular Morphology, 18, 244-249.
27. Loo, P. S., Thomas, S. C., Nicolson, M. C., Fyfe, M. N., & Kerr, K. M. (2010). Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens. Journal of Thoracic Oncology, 5, 442-447.
28. Ye, J., Findeis-Hosey, J. J., Yang, Q., McMahon, L. A., Yao, J. L., Li, F., et al. (2011). Combination of napsin A and TTF-1 immunohistochemistry helps in differentiating primary lung adenocarcinoma from metastatic carcinoma in the lung. Applied Immunohistochemistry and Molecular Morphology, 19, 313-317.
29. Monica, V., Ceppi, P., Righi, L., Tavaglione, V., Volante, M., Pelosi, G., et al. (2009). Desmocollin-3: A new marker of squamous differentiation in undifferentiated large cell carcinoma of the lung. Modern Pathology, 22, 709-717.
30. Johnson, D. H., Fehrenbacher, L., Novotny, W. F., Herbst, R. S., Nemunaitis, J. J., Jablons, D. M., et al. (2004). Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non small-cell lung cancer. Journal of Clinical Oncology, 22, 2184-2191.
31. Sandler, A. B., Schiller, J. H., Gray, R., Dimery, I., Brahmer, J., Samant, M., et al. (2009). Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with carboplatin and paclitaxel plus bevacizumab. Journal of Clinical Oncology, 27, 1405-1412.
32. Socinski, M. A., Novello, S., Brahmer, J. R., Rosell, R., Sanchez, J. M., Belani, C. P., et al. (2008). Multicenter, phase II trial of sunitinib in previously treated, advanced nonsmall-cell lung cancer. Journal of Clinical Oncology, 26, 650-656.
33. Travis, W. D., Brambilla, E., Noguchi, M., Nicholson, A. G., Geisinger, K. R., Yatabe, Y., et al. (2011). International association for the study of lung cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. Journal of Thoracic Oncology, 6, 244-285.
34. Gorenstein, L. A., & Sonett, J. R. (2011). The surgical management of stage I and stage II lung cancer. Surgical Oncology Clinics of North America, 20, 701-720.
35. Wright, G., Manser, R. L., Byrnes, G., Hart, D., & Campbell, D. A. (2006). Surgery for non-small cell lung cancer: Systematic review and meta-analysis of randomised controlled trials. Thorax, 61, 597-603.
36. Gospodarowicz, M. K., O'Sullivan, B., & Koh, E. S. (2009). Prognostic factors: Principles and applications. In Peter Goldstraw (Ed.), IASLC Manual Staging Manual in Thoracic Oncology (pp. 111-128). Orange Park, FL: Editorial Rx Press.
37. Daniels, A. C. (1949). A method of biopsy useful in diagnosing certain intrathoracic diseases. Diseases of the Chest, 16, 360-367.
38. Carlens, E. (1959). Mediastinoscopy: A method for inspection and tissue biopsy in the superior mediastinum. Diseases of the Chest, 36, 343-352.
39. McNeill, T. M., & Chamberlain, J. M. (1966). Diagnostic anterior mediastinotomy. Annals of Thoracic Surgery, 2, 532-539.
40. Little, A. G., Rusch, V. W., Bonner, J. A., Gaspar, L. E., Green, M. R., Webb, W. R., et al. (2005). Patterns of surgical care of lung cancer patients. Annals of Thoracic Surgery, 80, 2051-2056.
41. Silvestri, G. A., Gould, M. K., Margolis, M. L., Tanoue, L. T., McCrory, D., Toloza, E., et al. (2007). Non-invasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest, 132, 178S-201S.
42. Micames, C. G., McCrory, D. C., Pavey, D. A., Jowell, P. S., & Gress, F. G. (2007). Endoscopic ultrasound-guided fine-needle aspiration for non-small cell lung cancer staging: A systematic review and metaanalysis. Chest, 131, 539-548.
43. Herth, F. J., Lunn, W., Eberhardt, R., Becker, H. D., & Ernst, A. (2005). Transbronchial versus transesophageal ultrasound-guided aspiration of enlarged mediastinal lymph nodes. American Journal of Respiratory and Critical Care Medicine, 171, 1164-1167.
44. Hürtgen, M., Friedel, G., Toomes, H., & Fritz, P. (2002). Radical video-assisted mediastinoscopic lymphadenectomy (VAMLA)-technique and first results. European Journal of Cardio-Thoracic Surgery, 21, 348-351.
45. Riaz, S. P., Linklater, K. M., Page, R., Peake, M. D., Møller, H., & Lüchtenborg, M. (2012). Recent trends in resection rates among non-small cell lung cancer patients in England. Thorax, 67, 811-814.
46. Lamm, D. L., Thor, D. E., Harris, S. C., Reyna, J. A., Stogdill, V. D., & Radwin, H. M. (1980). Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer. Journal of Urology, 124, 38-42.
47. Millar, J. W., Roscoe, P., & Pearce, S. J. (1982). Five-year results of a controlled study of BCG immunotherapy after surgical resection in bronchogenic carcinoma. Thorax, 37, 57-60.
48. Patard, J. J., Saint, F., Velotti, F., Abbou, C. C., & Chopin, D. K. (1998). Immune response following intravesical bacillus Calmette-Guerin instillations in superficial madder cancer: A review. Urological Research, 26, 155-159.
49. Jansen, H. M., De Gast, G. C., & Esselink, M. T. (1978). Adjuvant immunotherapy with BCG in squamous-cell bronchial carcinoma. Immune reactivity in relation to immunostimulation (preliminary results in a controlled trial). Thorax, 33, 429-438.
50. Kaufmann, M., Stjernsward, J., & Zimmermann, A. (1985). Adverse effect of intrapleural Corynebacterium parvum as adjuvant therapy in resected Stage I and II non-small cell carcinoma of the lung. Journal of Thoracic and Cardiovascular Surgery, 89, 842-847.
51. O'Brien, M. E., Anderson, H., Kaukel, E., O'Byrne, K., Pawlicki, M., Von Pawel, J., et al. (2004). SRL172 (killed Mycobacterium vaccae) in addition to standard chemotherapy improves quality of life without affecting survival, in patients with advanced non-small-cell lung cancer: Phase III results. Annals of Oncology, 15, 906-914.
52. Stanford, J. L., Stanford, C. A., O'Brien, M. E., & Grange, J. M. (2008). Successful immunotherapy with Mycobacterium vaccae in the treatment of adenocarcinoma of the lung. European Journal of Cancer, 44, 224-227.
53. Forero, A., Meredith, R. F., Khazaeli, M. B., Shen, S., Grizzle, W. E., Carey, D., et al. (2005). Phase I study of 90Y-CC49 monoclonal antibody therapy in patients with advanced non-small cell lung cancer: Effect of chelating agents and paclitaxel co-administration. Cancer Biotherapy and Radiopharmaceuticals, 20, 467-478.
54. Grant, S. C., Kris, M. G., Houghton, A. N., & Chapman, P. B. (1999). Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guerin. Clinical Cancer Research, 5, 1319-1323.
55. Hernández, A. M., Toledo, D., Martínez, D., Griñán, T., Brito, V., Macías, A., et al. (2008). Characterization of the antibody response against NeuGcGM3 ganglioside elicited in non-small cell lung cancer patients immunized with an anti-idiotype antibody. The Journal of Immunology, 181, 6625-6634.
56. Arnould, L., Gelly, M., Penault-Llorca, F., Benoit, L., Bonnetain, F., Migeon, C., et al. (2006). Trastuzumab based treatment of HER2-positive breast cancer: An antibody-dependent cellular cytotoxicity mechanism? British Journal of Cancer, 94, 259-267.
57. Maulik, G., Kijima, T., & Salgia, R. (2003). Role of receptor tyrosine kinases in lung cancer. Methods in Molecular Medicine, 74, 113-125.
58. Grotzinger, J. (2002). Molecular mechanisms of cytokine receptor activation. Biochimica et Biophysica Acta, 1592, 215-223.
59. Pawson, T. (2002). Regulation and targets of receptor tyrosine kinases. European Journal of Cancer, 38(Suppl 5), S3-S10.
60. Hirsch, F. R., Scagliotti, G. V., Langer, C. J., Varella-Garcia, M., & Franklin, W. A. (2003). Epidermal growth factor family of receptors in preneoplasia and lung cancer: Perspectives for targeted therapies. Lung Cancer, 41(Suppl 1), S29-S42.
61. Levitzki, A. (2003). EGF receptor as a therapeutic target. Lung Cancer, 41(Suppl 1), S9-S14.
62. Fabbro, D., Ruetz, S., Buchdunger, E., Cowan-Jacob, S. W., Fendrich, G., Liebetanz, J., et al. (2002). Protein kinases as targets for anticancer agents: From inhibitors to useful drugs. Pharmacology and Therapeutics, 93, 79-98.
63. Davies, A. M., Gandara, D. R., Lara, P. N, Jr, Mack, P. C., Lau, D. H., & Gumerlock, P. H. (2003). Antisense oligonucleotides in the treatment of non-small-cell lung cancer. Clinical Lung Cancer, 4(Suppl 2), S68-S73.
64. Tong, A. W., Zhang, Y. A., Cunningham, C., Maples, P., & Nemunaitis, J. (2001). Potential clinical application of antioncogene ribozymes for human lung cancer. Clinical Lung Cancer, 2, 220-226.
65. Bhattacharjee, A., Richards, W. G., Staunton, J., Li, C., Monti, S., Vasa, P., et al. (2001). Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proceedings of the National Academy of Sciences United States of America, 98, 13790-13795.
66. Meyerson, M., & Carbone, D. (2005). Genomic and proteomic profiling of lung cancers: Lung cancer classification in the age of targeted therapy. Journal of Clinical Oncology, 23, 3219-3226.
67. Chen, H. Y., Yu, S. L., Chen, C. H., Chang, G. C., Chen, C. Y., Yuan, A., et al. (2007). A five-gene signature and clinical outcome in non-small-cell lung cancer. New England Journal of Medicine, 356, 11-20.
68. Patz, E. F, Jr, Campa, M. J., Gottlin, E. B., Kusmartseva, I., Guan, X. R., & Herndon, J. E, I. I. (2007). Panel of serum biomarkers for the diagnosis of lung cancer. Journal of Clinical Oncology, 25, 5578-5583.